| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
and ß Isoforms in Human Pituitary Tumors1
Division of Endocrinology and Metabolism, Department of Internal Medicine (M.A.S., L.K.P., A.Y.S., A.A.); Department of Neuropathology (M.B.L.); and Department of Neurosurgery (E.R.L.), University of Virginia Health Science Center, Charlottesville, Virginia 22908
Address all correspondence and requests for reprints to: Margaret A. Shupnik, Ph.D., Box 578 HSC, University of Virginia, Charlottesville, Virginia 22908. E-mail: mas3x{at}virginia.edu
The physiological effects of estrogen on the pituitary, including
cellular proliferation and regulation of hormone synthesis, are
mediated by the nuclear estrogen receptor (ER). The ER acts as a dimer
to modulate gene transcription and contains specific functional domains
encoded in different exons. Two separate, but related, forms of the
receptor (ER
and ERß) exist, with distinct tissue and cell
patterns of expression. Additional ER isoforms, generated by
alternative messenger ribonucleic acid (mRNA) exon splicing, have been
defined in several tissues and are postulated to play a role in
tumorigenesis or in modulating the estrogen response. We examined 71
human pituitary adenomas of varying phenotypes and 6 normal pituitary
specimens for ER mRNA forms by RT-PCR and hybridization blotting
analysis. All prolactinomas (n = 14) contained ER
, and several
contained ERß (5 of 14) mRNA. In comparison, 6 tumors that expressed
PRL and GH expressed ERß (4 of 6) more frequently than ER
(3 of
6). ERß mRNA was also found more frequently in null cell (8 of 24
ER
and 14 of 24 ERß) and gonadotrope (13 of 21 ER
and 18 of 21
ERß) tumors. Additionally, ERß was found in 4 of 6 tumors that
contained only GH, although ER
was not observed in this tumor type.
Expression of the two ER forms within a tumor type was overlapping, but
some tumors contained only 1 isoform. Expression of ER
mRNA splice
variants also varied with cell type. All normal pituitaries contained
ER
deletions of exon 4, 5, and 7, whereas only 2 of 6 samples
contained the exon 2 deletion variant. Although the same ER
mRNA
variants were observed among the various tumor types, the proportion of
specific splice variants expressed varied. For example, most
ER-positive prolactinomas expressed ER
variants with deletions of
exon 2, 4, or 5, whereas gonadotropin tumors preferentially expressed
the ER
exon 7 deletion variant. A novel ERß mRNA splice variant,
missing exon 2, was observed in a majority of all ERß-positive
tumors. Immunoblotting analysis of ER
and ERß proteins supported
the mRNA results. Because ER
and ERß have different biological
responses to selective ER modulators, and the ER deletion variants have
biological effects distinct from those of the full-length ER,
expression of these isoforms may influence the biological properties of
these tumors and affect their ability to respond to estrogen and
antiestrogen therapies.
This article has been cited by other articles:
![]() |
C. Montani, M. Penza, M. Jeremic, G. Biasiotto, G. La Sala, M. De Felici, P. Ciana, A. Maggi, and D. Di Lorenzo Genistein is an Efficient Estrogen in the Whole-Body throughout Mouse Development Toxicol. Sci., May 1, 2008; 103(1): 57 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cosma, J. Bailey, J. M. Miles, C. Y. Bowers, and J. D. Veldhuis Pituitary and/or Peripheral Estrogen-Receptor {alpha} Regulates Follicle-Stimulating Hormone Secretion, Whereas Central Estrogenic Pathways Direct Growth Hormone and Prolactin Secretion in Postmenopausal Women J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 951 - 958. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ben-Jonathan, C. R. LaPensee, and E. W. LaPensee What Can We Learn from Rodents about Prolactin in Humans? Endocr. Rev., February 1, 2008; 29(1): 1 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Veldhuis, D. M. Keenan, and C. Y. Bowers Peripheral estrogen receptor-{alpha} selectively modulates the waveform of GH secretory bursts in healthy women Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1514 - R1521. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Arreguin-Arevalo, T. L. Davis, and T. M. Nett Differential Modulation of Gonadotropin Secretion by Selective Estrogen Receptor 1 and Estrogen Receptor 2 Agonists in Ovariectomized Ewes Biol Reprod, August 1, 2007; 77(2): 320 - 328. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Ohnemus, M. Uenalan, J. Inzunza, J.-A. Gustafsson, and R. Paus The Hair Follicle as an Estrogen Target and Source Endocr. Rev., October 1, 2006; 27(6): 677 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M.A. Dreijerink, K. W. Mulder, G. S. Winkler, J. W.M. Hoppener, C. J.M. Lips, and H.Th. M. Timmers Menin Links Estrogen Receptor Activation to Histone H3K4 Trimethylation. Cancer Res., May 1, 2006; 66(9): 4929 - 4935. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, and C. Y. Bowers Somatotropic and Gonadotropic Axes Linkages in Infancy, Childhood, and the Puberty-Adult Transition Endocr. Rev., April 1, 2006; 27(2): 101 - 140. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Lee and J L. Jameson Gene therapy of pituitary diseases J. Endocrinol., June 1, 2005; 185(3): 353 - 362. [Abstract] [Full Text] [PDF] |
||||
![]() |
P L Hanson, S J B Aylwin, J P Monson, and J M Burrin FSH secretion predominates in vivo and in vitro in patients with non-functioning pituitary adenomas Eur. J. Endocrinol., March 1, 2005; 152(3): 363 - 370. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Xu, Q. Pan-Hammarstrom, A. Forsti, K. Hemminki, L. Hammarstrom, D. Labuda, J.-A. Gustafsson, and K. Dahlman-Wright Human Estrogen Receptor {beta} 548 Is Not a Common Variant in Three Distinct Populations Endocrinology, August 1, 2003; 144(8): 3541 - 3546. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Schreihofer, D. F. Rowe, E. F. Rissman, E. M. Scordalakes, J.-a. Gustafsson, and M. A. Shupnik Estrogen Receptor-{alpha} (ER{alpha}), But Not ER{beta}, Modulates Estrogen Stimulation of the ER{alpha}-Truncated Variant, TERP-1 Endocrinology, November 1, 2002; 143(11): 4196 - 4202. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Lee, W. R. Duan, M. Jakacka, B. D. Gehm, and J. L. Jameson Dominant Negative ER Induces Apoptosis in GH4 Pituitary Lactotrope Cells and Inhibits Tumor Growth in Nude Mice Endocrinology, September 1, 2001; 142(9): 3756 - 3763. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Tiffoche, C. Vaillant, D. Schausi, and M.-L. Thieulant Novel Intronic Promoter in the Rat ER{alpha} Gene Responsible for the Transient Transcription of a Variant Receptor Endocrinology, September 1, 2001; 142(9): 4106 - 4119. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Nealen, K. V. Vijayan, E. Bolton, and P. F. Bray Human Platelets Contain a Glycosylated Estrogen Receptor {beta} Circ. Res., March 2, 2001; 88(4): 438 - 442. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Campbell-Thompson, I. J. Lynch, and B. Bhardwaj Expression of Estrogen Receptor (ER) Subtypes and ER{beta} Isoforms in Colon Cancer Cancer Res., January 1, 2001; 61(2): 632 - 640. [Abstract] [Full Text] |
||||
![]() |
M. G. Ghosh, D. A. Thompson, and R. J. Weigel PDZK1 and GREB1 Are Estrogen-regulated Genes Expressed in Hormone-responsive Breast Cancer1, 2 Cancer Res., November 1, 2000; 60(22): 6367 - 6375. [Abstract] [Full Text] |
||||
![]() |
D. A. Schreihofer, M. H. Stoler, and M. A. Shupnik Differential Expression and Regulation of Estrogen Receptors (ERs) in Rat Pituitary and Cell Lines: Estrogen Decreases ER{alpha} Protein and Estrogen Responsiveness Endocrinology, June 1, 2000; 141(6): 2174 - 2184. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Resnick, D. A. Schreihofer, A. Periasamy, and M. A. Shupnik Truncated Estrogen Receptor Product-1 Suppresses Estrogen Receptor Transactivation by Dimerization with Estrogen Receptors alpha and beta J. Biol. Chem., March 15, 2000; 275(10): 7158 - 7166. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Couse and K. S. Korach Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us? Endocr. Rev., June 1, 1999; 20(3): 358 - 417. [Abstract] [Full Text] |
||||
![]() |
E. Leygue, H. Dotzlaw, P. H. Watson, and L. C. Murphy Expression of Estrogen Receptor {beta}1, {beta}2, and {beta}5 Messenger RNAs in Human Breast Tissue Cancer Res., March 1, 1999; 59(6): 1175 - 1179. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |